E

Electra Therapeutics, Inc.

ETRAPriced

Electra Therapeutics, Inc. · Nasdaq Global Select Market · Research source · 424B4 · 2026-09-18 · Latest filing · 10-Q · 2026-11-12 SEC ↗

Report source
Research source · 424B4 · 2026-09-18
SummaryBASIC RESEARCHReport source · 424B4

IPO research

Electra Therapeutics’ filed 424B4 prospectus describes a $15.00-per-share IPO of 23,333,334 common shares, with expected delivery on or about September 21, 2026, subject to completion conditions.

Full source-backed summary

As of the September 17, 2026 prospectus and September 18, 2026 filing, Electra Therapeutics is offering a priced IPO of common stock to fund late-stage clinical development, but remains pre-revenue, loss-making, dependent on clinical and regulatory execution, and subject to substantial financing and manufacturing risks. The filing does not establish that trading or closing has occurred.

Electra Therapeutics’ filed 424B4 prospectus describes a $15.00-per-share IPO of 23,333,334 common shares, with expected delivery on or about September 21, 2026, subject to completion conditions.

Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointExpected share delivery is on or about September 21, 2026; this is a prospectus expectation, not confirmation of closing or trading. The underwriter option may be exercised within 30 days of the prospectus date.424B4 · 2026-09-18
Business and development direction

Electra Therapeutics, Inc.

Current business
Future development
DECISION DRIVERS

Key risks

Risk 1

Positive early clinical results may not predict registrational or later-stage outcomes; enrollment and regulatory approval remain uncertain.

Risk 2

The company states it has no approved products, no revenue and expects significant future losses; additional capital may be required even after the offering.

Risk 3

The CMO facility received FDA Form 483 observations and OAI classification; remediation and shutdown timing are uncertain and could delay a BLA.

Next checkExpected share delivery is on or about September 21, 2026; this is a prospectus expectation, not confirmation of closing or trading. The underwriter option may be exercised within 30 days of the prospectus date.
Latest filing2026-11-12
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualitySome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
CONFIRMED
#InstitutionUnderwriting allocationRatio · calculatedShares
1Jefferies LLC35.50%8,283,334 shares
2TD Securities (USA) LLC28.00%6,533,334 shares
3Evercore Group L.L.C.20.50%4,783,333 shares
4Cantor Fitzgerald & Co.16.00%3,733,333 shares

Ratio = institution commitment ÷ complete source-table total (23,333,334 shares) × 100.

Source and calculation

Allocation ratios are calculated from each reported commitment and the complete total in the same source table; they are not ownership or fee percentages.

Underwriting purchase commitments as disclosed; shares; source class retained in the column header; source column: NUMBER OFSHARES

NUMBER OFSHARES

SEC table 627 row 8; source 1703336:1706858; SHA256 f00164e138057c1bdc19818f73569f4c9b3ca0787792a56323c82e9639d6ead4

Jefferies LLC: 8283334 / 23333334 × 100

TD Securities (USA) LLC: 6533334 / 23333334 × 100

Evercore Group L.L.C.: 4783333 / 23333334 × 100

Cantor Fitzgerald & Co.: 3733333 / 23333334 × 100

Source · 424B4 ↗

Underwriting terms

Underwriting terms
MeasureReported valueUnit
Underwriting discount per share$1.05$ / share
Total underwriting discount$24,500,001$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Underwriting discount per share

Base prospectus offering; cover per-share and total columns

SEC table 1 row 4; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Total underwriting discount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 4; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗

IPO CAPITAL QUALITY

Offering price $ / share$15
Gross offering amount $$350,000,010
Shares offered Shares23,333,334
Underwriting discount per share $ / share$1.05
Basis and evidence

424B4 · 2026-09-18

Electra Therapeutics’ filed 424B4 prospectus describes a $15.00-per-share IPO of 23,333,334 common shares, with expected delivery on or about September 21, 2026, subject to completion conditions.

Offering structure

Offering terms
MeasureReported valueUnit
Shares offered23,333,334Shares
Offering price$15$ / share
Gross offering amount$350,000,010$
Source and calculation

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

Shares offered

Prospectus offering table; stated base scenario and source conditions

SEC table 33 row 1; source 79167:79528; SHA256 649924c708c48b3901933b97d3774de549b7c2ca389f6ff3f7f939e58f53ae23 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Gross offering amount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 3; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Use of proceedsSource-linked structured inputs are not yet available. Open filing ↗

Dilution and valuation

IPO price$15Final
Basic post-offer≈ 62.767M
Equity value≈ $941.5043M
Dilution and valuation
CalculationSharesValueReference
Base post-offer valuation≈ 62.767M≈ $941.5043M
Derived calculationFinalshares · $Basis and evidence 10 ↗
Post-offer shares — base/no option62,766,955—
Reported sourcePost-offer · BasesharesBasis and evidence 8 ↗
Post-offer shares — full option66,266,955—
Reported sourcePost-offer · Full optionsharesBasis and evidence 8 ↗
Capitalization shares — actual29,329—
Reported sourceCommon stock; actualsharesBasis and evidence 3 ↗
Capitalization shares — pro forma39,433,621—
Reported sourceCommon stock; pro formasharesBasis and evidence 4 ↗
Capitalization shares — pro forma as adjusted62,766,955—
Reported sourceCommon stock; pro forma as adjustedsharesBasis and evidence 5 ↗
Shares offered23,333,334—
Reported sourcesharesBasis and evidence 6 ↗
Offering price—$15
Reported sourceFinal$/shareBasis and evidence 7 ↗
Gross offering amount—$350,000,010
Reported source$Basis and evidence 7 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 35 row 1 columns 2; share summary; label column 1; source 80299:80799; SHA256 f40a9c934382bb249aa9e9a52bb04ef6a753968d343b3b5fbddf9999b66cd14e ↗

Basis and evidence 2

Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 35 row 1 columns 2; share summary; label column 1; source 80299:80799; SHA256 f40a9c934382bb249aa9e9a52bb04ef6a753968d343b3b5fbddf9999b66cd14e ↗

Basis and evidence 3

Capitalization share count; source stage: actual; Common stock, $0.0001 par value; 71,000,000 shares authorized, 29,329 shares issued and outstanding, actual; 900,000,000 shares authorized, pro forma and pro forma as adjusted; 39,433,621 shares issued and outstanding, pro forma; 62,766,955 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 289 row 11 columns 1; share summary; label column 1; source 717185:732028; SHA256 70f13a0965705a0474e8e619aa271b966feca987367cca756c2250e095c740d1 ↗

Basis and evidence 4

Capitalization share count; source stage: pro forma; Common stock, $0.0001 par value; 71,000,000 shares authorized, 29,329 shares issued and outstanding, actual; 900,000,000 shares authorized, pro forma and pro forma as adjusted; 39,433,621 shares issued and outstanding, pro forma; 62,766,955 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 289 row 11 columns 1; share summary; label column 1; source 717185:732028; SHA256 70f13a0965705a0474e8e619aa271b966feca987367cca756c2250e095c740d1 ↗

Basis and evidence 5

Capitalization share count; source stage: pro forma as adjusted; Common stock, $0.0001 par value; 71,000,000 shares authorized, 29,329 shares issued and outstanding, actual; 900,000,000 shares authorized, pro forma and pro forma as adjusted; 39,433,621 shares issued and outstanding, pro forma; 62,766,955 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 289 row 11 columns 1; share summary; label column 1; source 717185:732028; SHA256 70f13a0965705a0474e8e619aa271b966feca987367cca756c2250e095c740d1 ↗

Basis and evidence 6

Prospectus offering table; stated base scenario and source conditions

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

SEC table 33 row 1; source 79167:79528; SHA256 649924c708c48b3901933b97d3774de549b7c2ca389f6ff3f7f939e58f53ae23 ↗

Basis and evidence 7

Base prospectus offering; cover per-share and total columns

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

SEC table 1 row 3; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗

Basis and evidence 8

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Offering price: $15

Exact input · Post-offer shares — base/no option: 62,766,955

Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — full option: 66,266,955

SEC table 1 row 3; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗

SEC table 35 row 1 columns 2; share summary; label column 1; source 80299:80799; SHA256 f40a9c934382bb249aa9e9a52bb04ef6a753968d343b3b5fbddf9999b66cd14e ↗

SEC valuation summary conditions; source 75707:79096; SHA256 53fd8c68b8924490b13375a81627c89c56ac0a048e69c3804af24c41860fb3f8 ↗

SEC valuation summary conditions; source 83873:129490; SHA256 21a2130f9b3c857ac09d98513fa58e74abcd5c57c53ffc15c0c26a23aa24fbb9 ↗

Basis and evidence 9

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

SEC table 1 row 3; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗

SEC table 35 row 1 columns 2; share summary; label column 1; source 80299:80799; SHA256 f40a9c934382bb249aa9e9a52bb04ef6a753968d343b3b5fbddf9999b66cd14e ↗

SEC valuation summary conditions; source 75707:79096; SHA256 53fd8c68b8924490b13375a81627c89c56ac0a048e69c3804af24c41860fb3f8 ↗

SEC valuation summary conditions; source 83873:129490; SHA256 21a2130f9b3c857ac09d98513fa58e74abcd5c57c53ffc15c0c26a23aa24fbb9 ↗

Basis and evidence 10

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — base/no option: 62,766,955

Exact input · Offering price: $15

SEC table 1 row 3; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗

SEC table 35 row 1 columns 2; share summary; label column 1; source 80299:80799; SHA256 f40a9c934382bb249aa9e9a52bb04ef6a753968d343b3b5fbddf9999b66cd14e ↗

SEC valuation summary conditions; source 75707:79096; SHA256 53fd8c68b8924490b13375a81627c89c56ac0a048e69c3804af24c41860fb3f8 ↗

SEC valuation summary conditions; source 83873:129490; SHA256 21a2130f9b3c857ac09d98513fa58e74abcd5c57c53ffc15c0c26a23aa24fbb9 ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Offering completion · $15 × ≈ 62.767M shares · Final

Implied equity value≈ $941.5043MPrice × post-offer shares
Post-offer shares≈ 62.767MShare count, not tradable float
Existing-holder ownership reduction0.0%Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

$15 × 62,766,955 = $941,504,325 [summary-table-35-base-1-price, summary-table-35-base-1-post]

Exact calculation · Derived whole-issuer equity value: $941,504,325

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesSome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
As of
2026-09-18
!After the offering, Electra officers, directors, pre-offering 5% holders and affiliates are expected to hold approximately 33.1%, assuming no group purchases. Principal-stockholder data are based on August 1, 2026 and include conversion shares; the excerpts do not provide a complete voting-rights reconciliation.View source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · Electra Therapeutics, Inc.
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
our executive officers, directors and stockholders whoOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group); source scope: of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partitionDisclosedEvidence
our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliatesOwnership as disclosed—approximately 33.1%Beneficial—
Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group); source scope: of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immed; not an additive ownership partitionDisclosedEvidence
WestlakeOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: holds; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Electra Therapeutics LLCBeneficial shares15,065,741——
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBERDisclosedEvidence
Entities affiliated with OrbiMedBeneficial shares3,549,527——
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBERDisclosedEvidence
Entities affiliated with OrbiMedBeneficial shares5,551,837——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Entities affiliated with Westlake BioPartners Fund I, L.P.Beneficial shares2,820,403——
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBERDisclosedEvidence
Entities affiliated with Westlake BioPartners Fund I, L.P.Beneficial shares6,347,539——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Redmile Biopharma Investments II, L.P.Beneficial shares2,811,887——
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBERDisclosedEvidence
Redmile Biopharma Investments II, L.P.Beneficial shares4,796,215——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Aventis Inc.Beneficial shares2,461,948——
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBERDisclosedEvidence
Aventis Inc.Beneficial shares2,461,948——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
LSP 7 Coöperatief U.A.Beneficial shares2,461,948——
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBERDisclosedEvidence
LSP 7 Coöperatief U.A.Beneficial shares2,461,948——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Entities affiliated with New Leaf VenturesBeneficial shares1,722,233——
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBERDisclosedEvidence
Electra Therapeutics LLCBeneficial ownership—38.2%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGEDisclosedEvidence
Entities affiliated with OrbiMedBeneficial ownership—9%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGEDisclosedEvidence
Entities affiliated with OrbiMedBeneficial ownership—8.8%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Entities affiliated with Westlake BioPartners Fund I, L.P.Beneficial ownership—7.1%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGEDisclosedEvidence
Entities affiliated with Westlake BioPartners Fund I, L.P.Beneficial ownership—10.1%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Redmile Biopharma Investments II, L.P.Beneficial ownership—7.1%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGEDisclosedEvidence
Redmile Biopharma Investments II, L.P.Beneficial ownership—7.6%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Aventis Inc.Beneficial ownership—6.2%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGEDisclosedEvidence
Aventis Inc.Beneficial ownership—3.9%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
LSP 7 Coöperatief U.A.Beneficial ownership—6.2%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGEDisclosedEvidence
LSP 7 Coöperatief U.A.Beneficial ownership—3.9%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Entities affiliated with New Leaf VenturesBeneficial ownership—4.4%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGEDisclosedEvidence
Entities affiliated with New Leaf VenturesBeneficial shares3,248,304——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Quehuong (Kathy) Dong, Pharm.D., M.B.A.Beneficial shares1,399,175——
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBERDisclosedEvidence
Quehuong (Kathy) Dong, Pharm.D., M.B.A.Beneficial shares1,854,659——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Gary S. Koe, Ph.D.Beneficial shares380,837——
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBERDisclosedEvidence
Gary S. Koe, Ph.D.Beneficial shares444,493——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Kim-Hien Dao, D.O., Ph.D.Beneficial shares547,202——
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBERDisclosedEvidence
Kim-Hien Dao, D.O., Ph.D.Beneficial shares547,202——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Matthew Fust, M.B.A.Beneficial shares136,800——
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBERDisclosedEvidence
Matthew Fust, M.B.A.Beneficial shares136,800——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Carl L. Gordon, Ph.D., C.F.A.Beneficial shares3,549,527——
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBERDisclosedEvidence
Carl L. Gordon, Ph.D., C.F.A.Beneficial shares5,551,837——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Beth Seidenberg, M.D.Beneficial shares2,820,403——
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBERDisclosedEvidence
Entities affiliated with New Leaf VenturesBeneficial ownership—5.2%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Quehuong (Kathy) Dong, Pharm.D., M.B.A.Beneficial ownership—3.4%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGEDisclosedEvidence
Quehuong (Kathy) Dong, Pharm.D., M.B.A.Beneficial ownership—3%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Kim-Hien Dao, D.O., Ph.D.Beneficial ownership—1.4%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGEDisclosedEvidence
Carl L. Gordon, Ph.D., C.F.A.Beneficial ownership—9%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGEDisclosedEvidence
Carl L. Gordon, Ph.D., C.F.A.Beneficial ownership—8.8%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Beth Seidenberg, M.D.Beneficial ownership—7.1%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGEDisclosedEvidence
Beth Seidenberg, M.D.Beneficial ownership—10.1%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Nancy Stagliano, Ph.D.Beneficial ownership—1%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
All directors and executive officers as a group (10 persons)Beneficial ownership—23.2%Beneficial—
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGEDisclosedEvidence
All directors and executive officers as a group (10 persons)Beneficial ownership—24.4%Beneficial—
SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGEDisclosedEvidence
Beth Seidenberg, M.D.Beneficial shares6,347,539——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Nancy Stagliano, Ph.D.Beneficial shares383,352——
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBERDisclosedEvidence
Nancy Stagliano, Ph.D.Beneficial shares638,987——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
All directors and executive officers as a group (10 persons)Beneficial shares9,994,008——
SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBERDisclosedEvidence
All directors and executive officers as a group (10 persons)Beneficial shares16,383,733——
SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBERDisclosedEvidence
Executive officers, directors, pre-offering >5%stockholders and their respective affiliatesOwnership as disclosed—approximately 33.1%Beneficial—
Literal complete collective group; Immediately after offering; Approximately33.1%; June30,2026basis after preferred-stock conversion; no group purchases. Percentage applies to the source complete group, not any individual or truncated subgroup; full original conditions retained.DisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retainedDisclosedEvidence
Source and calculation ↗
our executive officers, directors and stockholders who · our executive officers, directors and stockholders who — Ownership as disclosed · >5%

Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group); source scope: of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition

Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 33.1% of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immediately prior to the closing of this offering, assuming no purchase of shares in this offering by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-395670 · SEC ownership paragraph; source 633357:634910; SHA256 f61d9b9d18ec0ba189b156058660834b2fa0c871d24cd3e81ea2755099d56a53 ↗

our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates · our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates — Ownership as disclosed · approximately 33.1%

Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group); source scope: of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immed; not an additive ownership partition

Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 33.1% of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immediately prior to the closing of this offering, assuming no purchase of shares in this offering by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-395670 · SEC ownership paragraph; source 633357:634910; SHA256 f61d9b9d18ec0ba189b156058660834b2fa0c871d24cd3e81ea2755099d56a53 ↗

Westlake · Westlake — Ownership as disclosed · >5%

Source statement; >; source predicate: holds; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Westlake holds more than 5% of our outstanding capital stock. Dr. Seidenberg, a member of our board of directors, is the sole managing director of Westlake BioPartners GP II, LLC, the general partner of Westlake. Dr. Seidenberg resigned from our board of directors as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.

0001193125-26-395670 · SEC ownership paragraph; source 1543905:1544391; SHA256 f9164054fef033d167cb5c3b16d36c9d5b43da05ab6624d2a6521043b65100b4 ↗

Electra Therapeutics LLC · Electra Therapeutics LLC — Beneficial shares · 15,065,741

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Electra Therapeutics LLC (1)

0001193125-26-395670 · SEC table 565 row 5 columns 4; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:3 ↗

Entities affiliated with OrbiMed · Entities affiliated with OrbiMed — Beneficial shares · 3,549,527

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Entities affiliated with OrbiMed (2)

0001193125-26-395670 · SEC table 565 row 6 columns 4; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:3 ↗

Entities affiliated with OrbiMed · Entities affiliated with OrbiMed — Beneficial shares · 5,551,837

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Entities affiliated with OrbiMed (2)

0001193125-26-395670 · SEC table 565 row 6 columns 12; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:9 ↗

Entities affiliated with Westlake BioPartners Fund I, L.P. · Entities affiliated with Westlake BioPartners Fund I, L.P. — Beneficial shares · 2,820,403

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Entities affiliated with Westlake BioPartners Fund I, L.P. (3)

0001193125-26-395670 · SEC table 565 row 7 columns 4; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:3 ↗

Entities affiliated with Westlake BioPartners Fund I, L.P. · Entities affiliated with Westlake BioPartners Fund I, L.P. — Beneficial shares · 6,347,539

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Entities affiliated with Westlake BioPartners Fund I, L.P. (3)

0001193125-26-395670 · SEC table 565 row 7 columns 12; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:9 ↗

Redmile Biopharma Investments II, L.P. · Redmile Biopharma Investments II, L.P. — Beneficial shares · 2,811,887

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Redmile Biopharma Investments II, L.P. (4)

0001193125-26-395670 · SEC table 565 row 8 columns 4; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:3 ↗

Redmile Biopharma Investments II, L.P. · Redmile Biopharma Investments II, L.P. — Beneficial shares · 4,796,215

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Redmile Biopharma Investments II, L.P. (4)

0001193125-26-395670 · SEC table 565 row 8 columns 12; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:9 ↗

Aventis Inc. · Aventis Inc. — Beneficial shares · 2,461,948

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Aventis Inc. (5)

0001193125-26-395670 · SEC table 565 row 9 columns 4; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:3 ↗

Aventis Inc. · Aventis Inc. — Beneficial shares · 2,461,948

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Aventis Inc. (5)

0001193125-26-395670 · SEC table 565 row 9 columns 12; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:9 ↗

LSP 7 Coöperatief U.A. · LSP 7 Coöperatief U.A. — Beneficial shares · 2,461,948

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: LSP 7 Coöperatief U.A. (6)

0001193125-26-395670 · SEC table 565 row 10 columns 4; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:3 ↗

LSP 7 Coöperatief U.A. · LSP 7 Coöperatief U.A. — Beneficial shares · 2,461,948

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: LSP 7 Coöperatief U.A. (6)

0001193125-26-395670 · SEC table 565 row 10 columns 12; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:9 ↗

Entities affiliated with New Leaf Ventures · Entities affiliated with New Leaf Ventures — Beneficial shares · 1,722,233

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Entities affiliated with New Leaf Ventures (7)

0001193125-26-395670 · SEC table 565 row 11 columns 4; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:3 ↗

Electra Therapeutics LLC · Electra Therapeutics LLC — Beneficial ownership · 38.2%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Electra Therapeutics LLC (1)

0001193125-26-395670 · SEC table 565 row 5 columns 8,9; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:6 ↗

Entities affiliated with OrbiMed · Entities affiliated with OrbiMed — Beneficial ownership · 9%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Entities affiliated with OrbiMed (2)

0001193125-26-395670 · SEC table 565 row 6 columns 8,9; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:6 ↗

Entities affiliated with OrbiMed · Entities affiliated with OrbiMed — Beneficial ownership · 8.8%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Entities affiliated with OrbiMed (2)

0001193125-26-395670 · SEC table 565 row 6 columns 16,17; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:12 ↗

Entities affiliated with Westlake BioPartners Fund I, L.P. · Entities affiliated with Westlake BioPartners Fund I, L.P. — Beneficial ownership · 7.1%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Entities affiliated with Westlake BioPartners Fund I, L.P. (3)

0001193125-26-395670 · SEC table 565 row 7 columns 8,9; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:6 ↗

Entities affiliated with Westlake BioPartners Fund I, L.P. · Entities affiliated with Westlake BioPartners Fund I, L.P. — Beneficial ownership · 10.1%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Entities affiliated with Westlake BioPartners Fund I, L.P. (3)

0001193125-26-395670 · SEC table 565 row 7 columns 16,17; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:12 ↗

Redmile Biopharma Investments II, L.P. · Redmile Biopharma Investments II, L.P. — Beneficial ownership · 7.1%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Redmile Biopharma Investments II, L.P. (4)

0001193125-26-395670 · SEC table 565 row 8 columns 8,9; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:6 ↗

Redmile Biopharma Investments II, L.P. · Redmile Biopharma Investments II, L.P. — Beneficial ownership · 7.6%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Redmile Biopharma Investments II, L.P. (4)

0001193125-26-395670 · SEC table 565 row 8 columns 16,17; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:12 ↗

Aventis Inc. · Aventis Inc. — Beneficial ownership · 6.2%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Aventis Inc. (5)

0001193125-26-395670 · SEC table 565 row 9 columns 8,9; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:6 ↗

Aventis Inc. · Aventis Inc. — Beneficial ownership · 3.9%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Aventis Inc. (5)

0001193125-26-395670 · SEC table 565 row 9 columns 16,17; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:12 ↗

LSP 7 Coöperatief U.A. · LSP 7 Coöperatief U.A. — Beneficial ownership · 6.2%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: LSP 7 Coöperatief U.A. (6)

0001193125-26-395670 · SEC table 565 row 10 columns 8,9; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:6 ↗

LSP 7 Coöperatief U.A. · LSP 7 Coöperatief U.A. — Beneficial ownership · 3.9%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: LSP 7 Coöperatief U.A. (6)

0001193125-26-395670 · SEC table 565 row 10 columns 16,17; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:12 ↗

Entities affiliated with New Leaf Ventures · Entities affiliated with New Leaf Ventures — Beneficial ownership · 4.4%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Entities affiliated with New Leaf Ventures (7)

0001193125-26-395670 · SEC table 565 row 11 columns 8,9; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:3,3:6 ↗

Entities affiliated with New Leaf Ventures · Entities affiliated with New Leaf Ventures — Beneficial shares · 3,248,304

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Entities affiliated with New Leaf Ventures (7)

0001193125-26-395670 · SEC table 565 row 11 columns 12; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:9 ↗

Quehuong (Kathy) Dong, Pharm.D., M.B.A. · Quehuong (Kathy) Dong, Pharm.D., M.B.A. — Beneficial shares · 1,399,175

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Quehuong (Kathy) Dong, Pharm.D., M.B.A. (8)

0001193125-26-395670 · SEC table 566 row 5 columns 4; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:3 ↗

Quehuong (Kathy) Dong, Pharm.D., M.B.A. · Quehuong (Kathy) Dong, Pharm.D., M.B.A. — Beneficial shares · 1,854,659

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Quehuong (Kathy) Dong, Pharm.D., M.B.A. (8)

0001193125-26-395670 · SEC table 566 row 5 columns 12; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:9 ↗

Gary S. Koe, Ph.D. · Gary S. Koe, Ph.D. — Beneficial shares · 380,837

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Gary S. Koe, Ph.D. (9)

0001193125-26-395670 · SEC table 566 row 6 columns 4; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:3 ↗

Gary S. Koe, Ph.D. · Gary S. Koe, Ph.D. — Beneficial shares · 444,493

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Gary S. Koe, Ph.D. (9)

0001193125-26-395670 · SEC table 566 row 6 columns 12; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:9 ↗

Kim-Hien Dao, D.O., Ph.D. · Kim-Hien Dao, D.O., Ph.D. — Beneficial shares · 547,202

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Kim-Hien Dao, D.O., Ph.D. (10)

0001193125-26-395670 · SEC table 566 row 7 columns 4; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:3 ↗

Kim-Hien Dao, D.O., Ph.D. · Kim-Hien Dao, D.O., Ph.D. — Beneficial shares · 547,202

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Kim-Hien Dao, D.O., Ph.D. (10)

0001193125-26-395670 · SEC table 566 row 7 columns 12; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:9 ↗

Matthew Fust, M.B.A. · Matthew Fust, M.B.A. — Beneficial shares · 136,800

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Matthew Fust, M.B.A. (11)

0001193125-26-395670 · SEC table 566 row 8 columns 4; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:3 ↗

Matthew Fust, M.B.A. · Matthew Fust, M.B.A. — Beneficial shares · 136,800

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Matthew Fust, M.B.A. (11)

0001193125-26-395670 · SEC table 566 row 8 columns 12; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:9 ↗

Carl L. Gordon, Ph.D., C.F.A. · Carl L. Gordon, Ph.D., C.F.A. — Beneficial shares · 3,549,527

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Carl L. Gordon, Ph.D., C.F.A. (13)

0001193125-26-395670 · SEC table 566 row 10 columns 4; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:3 ↗

Carl L. Gordon, Ph.D., C.F.A. · Carl L. Gordon, Ph.D., C.F.A. — Beneficial shares · 5,551,837

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Carl L. Gordon, Ph.D., C.F.A. (13)

0001193125-26-395670 · SEC table 566 row 10 columns 12; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:9 ↗

Beth Seidenberg, M.D. · Beth Seidenberg, M.D. — Beneficial shares · 2,820,403

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Beth Seidenberg, M.D. (14)

0001193125-26-395670 · SEC table 566 row 11 columns 4; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:3 ↗

Entities affiliated with New Leaf Ventures · Entities affiliated with New Leaf Ventures — Beneficial ownership · 5.2%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Entities affiliated with New Leaf Ventures (7)

0001193125-26-395670 · SEC table 565 row 11 columns 16,17; source 1572156:1581564; SHA256 3573e92b2d6fa896c91ec1b1b0de608e43e11b048c479665e3697b13305efd66; ownership header cells 2:6,3:12 ↗

Quehuong (Kathy) Dong, Pharm.D., M.B.A. · Quehuong (Kathy) Dong, Pharm.D., M.B.A. — Beneficial ownership · 3.4%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: Quehuong (Kathy) Dong, Pharm.D., M.B.A. (8)

0001193125-26-395670 · SEC table 566 row 5 columns 8,9; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:6 ↗

Quehuong (Kathy) Dong, Pharm.D., M.B.A. · Quehuong (Kathy) Dong, Pharm.D., M.B.A. — Beneficial ownership · 3%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Quehuong (Kathy) Dong, Pharm.D., M.B.A. (8)

0001193125-26-395670 · SEC table 566 row 5 columns 16,17; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:12 ↗

Kim-Hien Dao, D.O., Ph.D. · Kim-Hien Dao, D.O., Ph.D. — Beneficial ownership · 1.4%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: Kim-Hien Dao, D.O., Ph.D. (10)

0001193125-26-395670 · SEC table 566 row 7 columns 8,9; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:6 ↗

Carl L. Gordon, Ph.D., C.F.A. · Carl L. Gordon, Ph.D., C.F.A. — Beneficial ownership · 9%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: Carl L. Gordon, Ph.D., C.F.A. (13)

0001193125-26-395670 · SEC table 566 row 10 columns 8,9; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:6 ↗

Carl L. Gordon, Ph.D., C.F.A. · Carl L. Gordon, Ph.D., C.F.A. — Beneficial ownership · 8.8%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Carl L. Gordon, Ph.D., C.F.A. (13)

0001193125-26-395670 · SEC table 566 row 10 columns 16,17; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:12 ↗

Beth Seidenberg, M.D. · Beth Seidenberg, M.D. — Beneficial ownership · 7.1%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: Beth Seidenberg, M.D. (14)

0001193125-26-395670 · SEC table 566 row 11 columns 8,9; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:6 ↗

Beth Seidenberg, M.D. · Beth Seidenberg, M.D. — Beneficial ownership · 10.1%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Beth Seidenberg, M.D. (14)

0001193125-26-395670 · SEC table 566 row 11 columns 16,17; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:12 ↗

Nancy Stagliano, Ph.D. · Nancy Stagliano, Ph.D. — Beneficial ownership · 1%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Nancy Stagliano, Ph.D. (15)

0001193125-26-395670 · SEC table 566 row 12 columns 16,17; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:12 ↗

All directors and executive officers as a group (10 persons) · All directors and executive officers as a group (10 persons) — Beneficial ownership · 23.2%

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: All directors and executive officers as a group (10 persons) (16)

0001193125-26-395670 · SEC table 566 row 13 columns 8,9; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:6 ↗

All directors and executive officers as a group (10 persons) · All directors and executive officers as a group (10 persons) — Beneficial ownership · 24.4%

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: All directors and executive officers as a group (10 persons) (16)

0001193125-26-395670 · SEC table 566 row 13 columns 16,17; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:12 ↗

Beth Seidenberg, M.D. · Beth Seidenberg, M.D. — Beneficial shares · 6,347,539

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Beth Seidenberg, M.D. (14)

0001193125-26-395670 · SEC table 566 row 11 columns 12; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:9 ↗

Nancy Stagliano, Ph.D. · Nancy Stagliano, Ph.D. — Beneficial shares · 383,352

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Nancy Stagliano, Ph.D. (15)

0001193125-26-395670 · SEC table 566 row 12 columns 4; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:3 ↗

Nancy Stagliano, Ph.D. · Nancy Stagliano, Ph.D. — Beneficial shares · 638,987

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Nancy Stagliano, Ph.D. (15)

0001193125-26-395670 · SEC table 566 row 12 columns 12; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:9 ↗

All directors and executive officers as a group (10 persons) · All directors and executive officers as a group (10 persons) — Beneficial shares · 9,994,008

Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: All directors and executive officers as a group (10 persons) (16)

0001193125-26-395670 · SEC table 566 row 13 columns 4; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:3,3:3 ↗

All directors and executive officers as a group (10 persons) · All directors and executive officers as a group (10 persons) — Beneficial shares · 16,383,733

Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition

Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: All directors and executive officers as a group (10 persons) (16)

0001193125-26-395670 · SEC table 566 row 13 columns 12; source 1582049:1593817; SHA256 8e03fbf7a4e21883108ce2afa52d4769da4176b910cddde65e95ca70bf888807; ownership header cells 2:6,3:9 ↗

Executive officers, directors, pre-offering >5%stockholders and their respective affiliates · Executive officers, directors, pre-offering >5%stockholders and their respective affiliates — Ownership as disclosed · approximately 33.1%

Literal complete collective group; Immediately after offering; Approximately33.1%; June30,2026basis after preferred-stock conversion; no group purchases. Percentage applies to the source complete group, not any individual or truncated subgroup; full original conditions retained.

Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 33.1% of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immediately prior to the closing of this offering, assuming no purchase of shares in this offering by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-395670 · SEC ownership paragraph; source 633357:634910; SHA256 f61d9b9d18ec0ba189b156058660834b2fa0c871d24cd3e81ea2755099d56a53 ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained

Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of stockholders, except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. There are no cumulative voting rights. Source context: Upon the filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 900,000,000 shares of our common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective upon the closing of this offering, and of the DGCL. This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the DGCL.

0001193125-26-395670 · SEC ownership excerpt; source 1616018:1616392; SHA256 1ab3ad4ae5785eceb0871653530c0da32b7a4f66d4fe8337a6c7c89a082e75d9; context source 1613731:1614783; SHA256 76c837154a6f07f9e100c63fa7bdb2d8e819eb14da645b2b22af0ace85968150 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
Each of our officers, directors and substantially all of our stockholdersAfter date of this prospectus · Source conditions apply180 days
We, our directors, executive officers, and the holders of substantially all of our equity securities,After date of this prospectus · Source conditions apply180 days
Source and calculation
Each of our officers, directors and substantially all of our stockholders

Based on 39,433,621 shares of our capital stock outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, upon completion of this offering, we will have a total of 62,766,955 shares of common stock outstanding. Of these shares, only the 23,333,334 shares of common stock sold in this offering, or 26,833,334 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 39,433,621 shares outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, approximately all 39,433,621 shares of common stock will be eligible for sale in the public market, of which approximately 14,729,214 shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). See the section titled “Executive and Director Compensation—Narrative to Summary Compensation Table—Equity-based Incentive Awards” for additional information about Electra LLC. Prior to the closing of this offering, Electra LLC distributed shares of our Series A redeemable convertible preferred stock to the unit holders of Electra LLC, which includes certain of our officers, directors and their affiliated entities.

SEC lock-up paragraph; source 621547:624047; SHA256 2225dfcabaa3ef83fbd5e0984db6b2fe7330ff95b447eed817fd9ab20584234a ↗
We, our directors, executive officers, and the holders of substantially all of our equity securities,

We, our directors, executive officers, and the holders of substantially all of our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section titled “Underwriting,” we will not, except with the prior written consent of Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., and they will not, except with the prior written consent of Jefferies LLC and TD Securities (USA) LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to sell or otherwise dispose of, or transfer any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, request or demand that we file a registration statement related to our common stock, or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are subject to a market stand-off agreement with us, which imposes similar restrictions.

SEC lock-up paragraph; source 1663905:1665273; SHA256 316c0e61b8bb2bc34db2575f643d1d9dd6ab459888dd6c4d84d3a6417567d000 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

date of this prospectus

  1. Each of our officers, directors and substantially all of our stockholdersBased on 39,433,621 shares of our capital stock outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, upon completion of this offering, we will have a total of 62,766,955 shares of common stock outstanding. Of these shares, only the 23,333,334 shares of common stock sold in this offering, or 26,833,334 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 39,433,621 shares outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, approximately all 39,433,621 shares of common stock will be eligible for sale in the public market, of which approximately 14,729,214 shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). See the section titled “Executive and Director Compensation—Narrative to Summary Compensation Table—Equity-based Incentive Awards” for additional information about Electra LLC. Prior to the closing of this offering, Electra LLC distributed shares of our Series A redeemable convertible preferred stock to the unit holders of Electra LLC, which includes certain of our officers, directors and their affiliated entities.
  2. We, our directors, executive officers, and the holders of substantially all of our equity securities,We, our directors, executive officers, and the holders of substantially all of our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section titled “Underwriting,” we will not, except with the prior written consent of Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., and they will not, except with the prior written consent of Jefferies LLC and TD Securities (USA) LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to sell or otherwise dispose of, or transfer any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, request or demand that we file a registration statement related to our common stock, or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are subject to a market stand-off agreement with us, which imposes similar restrictions.
Holder / event
Holder / eventTerm / dateConditions
Each of our officers, directors and substantially all of our stockholders180 daysBased on 39,433,621 shares of our capital stock outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, upon completion of this offering, we will have a total of 62,766,955 shares of common stock outstanding. Of these shares, only the 23,333,334 shares of common stock sold in this offering, or 26,833,334 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 39,433,621 shares outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, approximately all 39,433,621 shares of common stock will be eligible for sale in the public market, of which approximately 14,729,214 shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). See the section titled “Executive and Director Compensation—Narrative to Summary Compensation Table—Equity-based Incentive Awards” for additional information about Electra LLC. Prior to the closing of this offering, Electra LLC distributed shares of our Series A redeemable convertible preferred stock to the unit holders of Electra LLC, which includes certain of our officers, directors and their affiliated entities.
We, our directors, executive officers, and the holders of substantially all of our equity securities,180 daysWe, our directors, executive officers, and the holders of substantially all of our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section titled “Underwriting,” we will not, except with the prior written consent of Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., and they will not, except with the prior written consent of Jefferies LLC and TD Securities (USA) LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to sell or otherwise dispose of, or transfer any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, request or demand that we file a registration statement related to our common stock, or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are subject to a market stand-off agreement with us, which imposes similar restrictions.
Basis and evidence
Each of our officers, directors and substantially all of our stockholders

Based on 39,433,621 shares of our capital stock outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, upon completion of this offering, we will have a total of 62,766,955 shares of common stock outstanding. Of these shares, only the 23,333,334 shares of common stock sold in this offering, or 26,833,334 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 39,433,621 shares outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, approximately all 39,433,621 shares of common stock will be eligible for sale in the public market, of which approximately 14,729,214 shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). See the section titled “Executive and Director Compensation—Narrative to Summary Compensation Table—Equity-based Incentive Awards” for additional information about Electra LLC. Prior to the closing of this offering, Electra LLC distributed shares of our Series A redeemable convertible preferred stock to the unit holders of Electra LLC, which includes certain of our officers, directors and their affiliated entities.

SEC lock-up paragraph; source 621547:624047; SHA256 2225dfcabaa3ef83fbd5e0984db6b2fe7330ff95b447eed817fd9ab20584234a ↗
We, our directors, executive officers, and the holders of substantially all of our equity securities,

We, our directors, executive officers, and the holders of substantially all of our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section titled “Underwriting,” we will not, except with the prior written consent of Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., and they will not, except with the prior written consent of Jefferies LLC and TD Securities (USA) LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to sell or otherwise dispose of, or transfer any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, request or demand that we file a registration statement related to our common stock, or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are subject to a market stand-off agreement with us, which imposes similar restrictions.

SEC lock-up paragraph; source 1663905:1665273; SHA256 316c0e61b8bb2bc34db2575f643d1d9dd6ab459888dd6c4d84d3a6417567d000 ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

$ · Annual values as reported
FY2024($24,786,000)
FY2025($61,975,000)

Operating cash flow

$ · Annual values as reported
FY2024($26,003,000)
FY2025($60,484,000)
Financial quality
CalculationFY2024FY2025
Net income / (loss)($24,786,000)($61,975,000)
Operating cash flow($26,003,000)($60,484,000)
Financial quality
CalculationReported value
Cash and cash equivalents2025-12-31$33,008,000
Cash and cash equivalents2024-12-31$14,787,000
Current assets2025-12-31$95,486,000
Current assets2024-12-31$19,420,000
Total assets2025-12-31$99,368,000
Total assets2024-12-31$19,420,000
Current liabilities2025-12-31$9,726,000
Current liabilities2024-12-31$4,195,000
Total liabilities2025-12-31$11,208,000
Total liabilities2024-12-31$4,195,000
Total equity / (deficit)2025-12-31($163,442,000)
Total equity / (deficit)2024-12-31($103,261,000)
General and administrative expensesFY2025$10,390,000
General and administrative expensesFY2024$5,241,000
Cash and cash equivalents2026-06-30 · Unaudited$66,507,000
Cash and cash equivalents2025-12-31 · Unaudited$33,008,000
Current assets2026-06-30 · Unaudited$100,361,000
Current assets2025-12-31 · Unaudited$95,486,000
Total assets2026-06-30 · Unaudited$106,498,000
Total assets2025-12-31 · Unaudited$99,368,000
Current liabilities2026-06-30 · Unaudited$13,626,000
Current liabilities2025-12-31 · Unaudited$9,726,000
Total liabilities2026-06-30 · Unaudited$14,782,000
Total liabilities2025-12-31 · Unaudited$11,208,000
Total equity / (deficit)2026-06-30 · Unaudited($219,455,000)
Total equity / (deficit)2025-12-31 · Unaudited($163,442,000)
Basis and evidence
Cash and cash equivalents
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
General and administrative
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
General and administrative
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net loss
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net loss
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net cash used in operating activities
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Cash and cash equivalents
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Cash and cash equivalents
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total current assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total current liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total stockholders’ deficit
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Financial quality and runway
Financial review

Financial quality and runway

The latest supplied period is the six months ended June 30, 2026, with balance-sheet data as of that date. The excerpts show R&D expense of $41.637 million and G&A expense of $8.593 million for the six months, cash, cash equivalents and marketable securities of $97.725 million, and accumulated deficit of $221.890 million. Full revenue, net-loss, debt and cash-flow totals are unavailable in the excerpts. A 2025 going-concern explanatory paragraph is disclosed.

Cash and cash equivalents$33,008,000
Cash and cash equivalents$14,787,000
Total current assets$95,486,000
EvidenceFinancial review 1

Six-month 2026 R&D expense was $41.637 million versus $18.792 million in six-month 2025; G&A was $8.593 million versus $5.921 million.

EvidenceFinancial review 2

June 30, 2026 cash, cash equivalents and marketable securities were $97.725 million before the offering and $417.575 million on a pro forma as-adjusted basis.

EvidenceFinancial review 3

The independent auditor’s 2025 report included a going-concern explanatory paragraph, creating a material financing dependency.

Source · The report of our independent registered public accounting firm included a “going concern” explanatory paragraphOpen 424B4 ↗
LATEST COMPARISON

MATERIAL CHANGES

The latest material signals and their investor impact are shown below.

Open 424B4 ↗
CHANGE 01Offering size and pricing finalized

Why it mattersBase shares increased from 21,666,667 to 23,333,334 and the expected price range was replaced by a $15.00 fixed price; the underwriter option increased from 3,250,000 to 3,500,000 shares.

Evidence · THE OFFERING
CHANGE 02Post-offering capitalization and proceeds updated

Why it mattersPost-offering shares increased from 61,100,288 to 62,766,955; estimated net proceeds increased from approximately $296.6 million to $319.9 million, excluding full exercise.

Evidence · THE OFFERING
CHANGE 03Dilution updated

Why it mattersReported dilution per new share decreased from $8.68 to $8.47, based on the final terms.

Evidence · Dilution
IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.

Loading filing history…

Risk 1

Positive early clinical results may not predict registrational or later-stage outcomes; enrollment and regulatory approval remain uncertain.

Risk 2

The company states it has no approved products, no revenue and expects significant future losses; additional capital may be required even after the offering.

Document424B40001193125-26-395670
Filed2026-09-18SEC EDGAR
Research updated2026-09-19Analysed
Source-bound table inputs96SEC EDGAR
Open filing ↗